Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ...
Business Insider

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients ...
Nasdaq

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...
Hosted on MSN

Alpha Tau expands Alpha DaRT into recurrent prostate cancer: What investors should watch

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is launching a new safety study titled “A Safety Study of ...
Nasdaq

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...
Hosted on MSN

Alpha Tau Medical’s innovative prostate cancer therapy: study completion update

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Alpha Tau Medical Ltd (DRTS) has recently completed a clinical study titled ‘A Feasibility of Neoadjuvant Interstitial ...
Science Daily

Scientists exploring potential new treatments for glioblastoma

A new approach to treating the most malignant type of brain cancer -- glioblastoma -- has shown strong promise in pre-clinical settings, raising hopes of increasing current average survival rates ...
Seeking Alpha

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (DRTS) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, today announced that the ...